Gilead Sciences, Inc. (LON:0QYQ)

Market Cap	115.31B
Revenue (ttm)	21.64B
Net Income (ttm)	6.03B
Shares Out	n/a
EPS (ttm)	4.78
PE Ratio	19.11
Forward PE	14.65
Dividend	2.38 (1.97%)
Ex-Dividend Date	Sep 15, 2025

Volume	3,305
Average Volume	5,233
Open	119.70
Previous Close	119.65
Day's Range	119.50 - 121.61
52-Week Range	86.11 - 125.48
Beta	0.35
RSI	59.26
Earnings Date	Oct 30, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 17,600
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QYQ

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD